Know Cancer

or
forgot password

Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans.


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Brain Cancer, Arthritis, Rheumatoid, Central Nervous System Neoplasms, Glioma

Thank you

Trial Information

Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans.


The success of cell and gene therapy depends on specific targeting of the therapeutic gene
or cell that is administered to the patient. Our goal is to develop an imaging method to
non-invasively monitor the location of the therapeutic gene or cell. Imaging should help in
the design of better protocols and potentially reduce side-effects of cell and gene therapy.


Inclusion Criteria:



- Clinical diagnosis of brain tumor or rheumatoid arthritis

Exclusion Criteria:

- Below 18 years of age

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

The primary endpoint of the study for each patient is acquisition of PET/CT image.

Outcome Time Frame:

Time of scan

Safety Issue:

No

Principal Investigator

Sanjiv Sam Gambhir M.D., Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Food and Drug Administration

Study ID:

BRNCNS0003

NCT ID:

NCT00185848

Start Date:

April 2005

Completion Date:

July 2013

Related Keywords:

  • Brain Cancer
  • Arthritis, Rheumatoid
  • Central Nervous System Neoplasms
  • Glioma
  • Arthritis
  • Arthritis, Rheumatoid
  • Brain Neoplasms
  • Neoplasms
  • Glioma
  • Nervous System Neoplasms
  • Central Nervous System Neoplasms

Name

Location

Stanford University School of MedicineStanford, California  94305-5317
University of California Los AngelesLos Angeles, California  90095-6951